Article Details
Retrieved on: 2025-03-16 23:28:46
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Sutro Biopharma (STRO) announced expanded data in a late-breaking oral presentation from the dose-optimization portion of the REFRalphaME-O1 tri.
Article found on: markets.businessinsider.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here